Top-Rated Stocks NASDAQ:DXCM DexCom - DXCM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $105.72 -1.00 (-0.94%) (As of 01/30/2023 04:04 PM ET) Add Compare Share Share Today's Range$105.08▼$106.9450-Day Range$104.00▼$122.6752-Week Range$66.89▼$134.76Volume1.16 million shsAverage Volume2.52 million shsMarket Capitalization$40.84 billionP/E Ratio194.88Dividend YieldN/APrice Target$121.94 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability DexCom MarketRank™ ForecastAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside15.3% Upside$121.94 Price TargetShort InterestBearish3.05% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.41Based on 15 Articles This WeekInsider TradingSelling Shares$6.29 M Sold Last QuarterProj. Earnings Growth32.91%From $0.79 to $1.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector347th out of 1,049 stocksSurgical & Medical Instruments Industry37th out of 105 stocks 2.4 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $121.94, DexCom has a forecasted upside of 15.3% from its current price of $105.79.Amount of Analyst CoverageDexCom has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.05% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in DexCom has recently increased by 1.03%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 2.5 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for DexCom this week, compared to 8 articles on an average week.Search InterestOnly 23 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows11 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,294,063.00 in company stock.Percentage Held by InsidersOnly 0.41% of the stock of DexCom is held by insiders.Percentage Held by Institutions94.01% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 32.91% in the coming year, from $0.79 to $1.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 195.01, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.26.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 195.01, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 106.11.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 18.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DexCom (NASDAQ:DXCM) StockDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Read More Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Stock News HeadlinesJanuary 18, 2023 | marketbeat.comInsulet Has Potential To Gain More Than Analysts Are Forecasting (DXCM)Even as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range.January 29, 2023 | americanbankingnews.comDexCom (NASDAQ:DXCM) Earns Outperform Rating from Analysts at Wolfe ResearchJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 28, 2023 | americanbankingnews.comDexCom (NASDAQ:DXCM) Rating Increased to Buy at StockNews.comJanuary 26, 2023 | americanbankingnews.comSteven Robert Pacelli Sells 412 Shares of DexCom, Inc. (NASDAQ:DXCM) StockJanuary 26, 2023 | americanbankingnews.comKevin R. Sayer Sells 45,607 Shares of DexCom, Inc. (NASDAQ:DXCM) StockJanuary 25, 2023 | finance.yahoo.comMasimo's (MASI) Patient Monitoring Devices Favored by New StudyJanuary 25, 2023 | americanbankingnews.comContrasting DexCom (NASDAQ:DXCM) and Vivos Therapeutics (NASDAQ:VVOS)January 30, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." January 24, 2023 | finance.yahoo.comDexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern TimeJanuary 20, 2023 | finance.yahoo.comDexCom (DXCM) Stock Benefited from Multiple Tailwinds in Q4January 11, 2023 | finance.yahoo.comAs Dexcom Settles, 2 Option Strategies Collect Premium, Minimize RiskJanuary 9, 2023 | finance.yahoo.com1 Top Growth Stock That Could Beat the Market In 2023 and BeyondJanuary 9, 2023 | finance.yahoo.comDexcom Appoints Teri Lawver as Chief Commercial OfficerJanuary 9, 2023 | finance.yahoo.comDexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 OutlookJanuary 6, 2023 | finance.yahoo.comDexCom (NASDAQ:DXCM) shareholders have earned a 51% CAGR over the last five yearsJanuary 3, 2023 | finance.yahoo.comDexcom to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | seekingalpha.comDexCom: Tremendous Growth ProspectsDecember 28, 2022 | finance.yahoo.comDexCom (DXCM) Stock Moves -0.1%: What You Should KnowDecember 23, 2022 | finance.yahoo.comDexCom (DXCM) Stock Moves -0.94%: What You Should KnowDecember 12, 2022 | finance.yahoo.comDexcom Canada Partners With Green Shield and The Health Depot to Offer Plan Members a Comprehensive Digital Diabetes Care ExperienceDecember 9, 2022 | finance.yahoo.comHave $1,000? 2 Smart Stocks to Buy in a Nasdaq Bear MarketDecember 8, 2022 | finance.yahoo.comDexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.December 8, 2022 | finance.yahoo.comIBD Stock Of The Day Dexcom: How A Key FDA Decision Could Make It ActionableDecember 5, 2022 | finance.yahoo.comDow Jones Leaders Caterpillar, Home Depot Headline These Best Stocks To WatchNovember 30, 2022 | finance.yahoo.comTruckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck DriversNovember 26, 2022 | finance.yahoo.comIs This Stock-Split Stock a Buy For 2023?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Company Calendar Last Earnings10/28/2021Today1/30/2023Next Earnings (Confirmed)2/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees7,000Year Founded1999Price Target and Rating Average Stock Price Forecast$121.94 High Stock Price Forecast$146.00 Low Stock Price Forecast$103.00 Forecasted Upside/Downside+15.3%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.5425 Trailing P/E Ratio194.88 Forward P/E Ratio133.82 P/E Growth2.92Net Income$154.70 million Net Margins8.24% Pretax Margin6.48% Return on Equity13.27% Return on Assets5.64% Debt Debt-to-Equity Ratio1.08 Current Ratio3.77 Quick Ratio3.43 Sales & Book Value Annual Sales$2.45 billion Price / Sales16.68 Cash Flow$0.94 per share Price / Cash Flow112.22 Book Value$5.81 per share Price / Book18.20Miscellaneous Outstanding Shares386,260,000Free Float384,674,000Market Cap$40.84 billion OptionableOptionable Beta1.14 Social Links Key ExecutivesMr. Kevin Ronald Sayer (Age 65)Exec. Chairman, CEO & Pres Comp: $2.39MMr. Jereme M. Sylvain (Age 43)Exec. VP, CFO & Chief Accounting Officer Comp: $783.16kMr. Jacob Steven Leach (Age 45)Exec. VP & COO Comp: $915.93kMr. Paul R. Flynn (Age 54)Exec. VP of Global Revenue Comp: $761.52kMr. Girish NaganathanExec. VP of R&D and CTOMr. Sean ChristensenDirector of Corp. Affairs & Head of Investor RelationsMr. Michael Brown (Age 53)Exec. VP & Chief Legal Officer Mr. Matthew Dolan (Age 42)Exec. VP of Strategy, Corp. Devel. & Dexcom Labs Ms. Sadie M. Stern (Age 48)Exec. VP & Chief HR Officer Mr. Andrew K. Balo (Age 75)Exec. VP of Global Medical Affairs, Access & Evidence More ExecutivesKey CompetitorsResMedNYSE:RMDBaxter InternationalNYSE:BAXInsuletNASDAQ:PODDAbiomedNASDAQ:ABMDBoston ScientificNYSE:BSXView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 1,444 shares on 1/30/2023Ownership: 0.293%Signaturefd LLCBought 966 shares on 1/30/2023Ownership: 0.002%Parnassus Investments LLCBought 1,889 shares on 1/30/2023Ownership: 0.000%James Investment Research Inc.Bought 239 shares on 1/30/2023Ownership: 0.000%Close Asset Management LtdBought 176 shares on 1/27/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions DXCM Stock - Frequently Asked Questions Should I buy or sell DexCom stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DXCM shares. View DXCM analyst ratings or view top-rated stocks. What is DexCom's stock price forecast for 2023? 13 Wall Street research analysts have issued twelve-month price targets for DexCom's shares. Their DXCM share price forecasts range from $103.00 to $146.00. On average, they anticipate the company's share price to reach $121.94 in the next year. This suggests a possible upside of 14.3% from the stock's current price. View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts. How have DXCM shares performed in 2023? DexCom's stock was trading at $113.24 on January 1st, 2023. Since then, DXCM stock has decreased by 5.8% and is now trading at $106.72. View the best growth stocks for 2023 here. When is DexCom's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023. View our DXCM earnings forecast. How can I listen to DexCom's earnings call? DexCom will be holding an earnings conference call on Thursday, February 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) announced its earnings results on Thursday, October, 28th. The medical device company reported $0.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.07. The medical device company had revenue of $650.20 million for the quarter, compared to analyst estimates of $617.07 million. DexCom had a trailing twelve-month return on equity of 13.27% and a net margin of 8.24%. The firm's revenue for the quarter was up 29.8% compared to the same quarter last year. During the same period last year, the business earned $0.24 earnings per share. Read the conference call transcript. When did DexCom's stock split? DexCom's stock split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What guidance has DexCom issued on next quarter's earnings? DexCom updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $815.00M-, compared to the consensus revenue estimate of $807.65 million. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP). What is DexCom's stock symbol? DexCom trades on the NASDAQ under the ticker symbol "DXCM." Who are DexCom's major shareholders? DexCom's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.48%), Allspring Global Investments Holdings LLC (0.35%), Beacon Investment Advisory Services Inc. (0.19%), Stephens Investment Management Group LLC (0.16%), Chicago Capital LLC (0.15%) and Peregrine Capital Management LLC (0.15%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DexCom's stock price today? One share of DXCM stock can currently be purchased for approximately $106.72. How much money does DexCom make? DexCom (NASDAQ:DXCM) has a market capitalization of $41.22 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $0.5425 on an earnings per share basis. How many employees does DexCom have? The company employs 7,000 workers across the globe. Does DexCom have any subsidiaries? The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.Read More How can I contact DexCom? DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201. This page (NASDAQ:DXCM) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.